BACK Servier signed a definitive agreement to acquire Symphogen Servier signed a definitive agreement to acquire Symphogen, a leading antibody discovery company, to boost its antibody capabilities and leverage its R&D pipeline Servier announced today that it has entered into a definitive agreement with the owners of Symphogen A/S, a leader in therapeutic antibody discovery, to acquire 100% of Symphogen’s share capital. The acquisition, the result of a process that has been underway for several months now, will strengthen Servier’s antibody capabilities and ensure that Symphogen’s antibody discovery and early-development platform is fully utilized. Under the terms of the agreement, Servier will gain full ownership of Symphogen’s proprietary pipeline of oncology and immuno-oncology programs and Symphogen’s antibody discovery and development platform. Following completion of the acquisition, Symphogen will become Servier’s antibody center of excellence for its therapeutic areas. Symphogen will operate as a standalone organization within the Servier Group, maintain its headquarters in Ballerup, Denmark, and continue to rely on its current and experienced employees. 06/04/2020 Other news © 2019 LES LABORATOIRES SERVIER This site is intended for United Kingdom residents Servier does not sell its products over the Internet Terms of Use Data Privacy Cookies notice Report a side effect Servier Clinical Trials M-NO-UK-00444 Date of Preparation January 2021